While speaking on her podcast Tea Time with Raven & Miranda, which she co-hosts with wife Miranda Pearman-Maday, the Disney ...

Raven-Symoné recalled having her first breast reduction when she was just 15 years old. While speaking on her podcast Tea ...

Raven-Symoné recalls being pushed to alter her body in order to get a television show at the tender age of 15.

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

The median time from breast cancer diagnosis to surgery was 0.8 years for risk-reducing mastectomies and three years for risk ...

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...

The company found that the 1 mg dose of Z-endoxifen reduced MBD by 17.3 percentage points, whereas the 2 mg dose achieved a reduction of 23.5 percentage points. Meanwhile, a minimal change of 0.27 ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...